---
title: "Weekly Recap | Alnylam Pharma +5.9%, consensus target above spot"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/301464331.md"
description: "Alnylam Pharma (ALNY) gained 5.9% this week to close at $232.68, against a 1.15% rise for the S&P 500 — outperforming by roughly 4.75 percentage points. The path was choppy early on: Monday opened at $218.36 and dipped to $215.46 before recovering, Tuesday pushed as high as $229.18, then Wednesday and Thursday saw repeated swings between $218 and $230. Friday closed near the week’s high at $232.68. Weekly range was 8%, and average daily volume of about 1."
datetime: "2026-10-10T06:02:03.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/301464331.md)
  - [en](https://longbridge.com/en/news/301464331.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/301464331.md)
generator: "portal-rs"
---

# Weekly Recap | Alnylam Pharma +5.9%, consensus target above spot

## The Week

Alnylam Pharma (ALNY) gained 5.9% this week to close at $232.68, against a 1.15% rise for the S&P 500 — outperforming by roughly 4.75 percentage points. The path was choppy early on: Monday opened at $218.36 and dipped to $215.46 before recovering, Tuesday pushed as high as $229.18, then Wednesday and Thursday saw repeated swings between $218 and $230. Friday closed near the week’s high at $232.68. Weekly range was 8%, and average daily volume of about 1.29 million shares sat roughly 10.9% below the median, so turnover was not heavy.

## Key Events

Biotech headlines kept Alnylam in view this week, mostly through the lens of an FDA complete response letter (CRL). On Tuesday 6 October, several outlets paired Regeneron’s Fast Track progress with Alnylam’s CRL hit, framing the split between biotech innovators gaining and losing momentum. Another piece the same day grouped Alnylam among stocks left out of prevailing baskets. No material company announcement surfaced during the week — no new product, earnings, or partnership disclosure  
 from the firm itself.

## Analyst Ratings

Coverage stands at 29 institutions: 16 rate it buy, 6 rate it overweight, and 7 rate it hold, with no underweight or sell ratings. The consensus rating is buy, and the consensus target price of $370.55 sits about 59.3% above the current price. Individual targets range from $256 to $536, showing wide disagreement. By industry ranking, Alnylam is 6th out of 508 biotech names.

## The Week Ahead

The calendar turns macro-heavy. On Tuesday 13 October, the US NFIB small business optimism index (prior 98.7) and annualised existing home sales (prior 3.98, forecast 3.96) are due. On Wednesday 14 October, CPI and core CPI arrive: core CPI prior 2.4 with forecast 2.5, headline CPI prior 3.4 with forecast 3.7. The read-through for biotech valuations will be in focus.

## In Short

With little fresh company news, ALNY rode sector sentiment higher this week. Ratings still point to a consensus buy with targets well above spot, but the spread of $256 to $536 shows real disagreement. In the latest session, small orders were the main net seller, while large and medium orders were smaller net buyers — participation looks retail-skewed. How price elasticity and target dispersion resolve around next week’s CPI is the main thread to watch.

*This article is generated by LongbridgeAI from market data, for information only and not investment advice.*

### Related Stocks

- [ALNY.US](https://longbridge.com/en/quote/ALNY.US.md)

## Related News & Research

- [SMC accepts vutrisiran for eligible patients in Scotland](https://longbridge.com/en/news/301569237.md)
- [Alnylam vs. Ionis: Here's the Better Bad-News Buy](https://longbridge.com/en/news/301476027.md)
- [Is ASML Holding NV's Stock a Buy Ahead of Its Q3 Earnings Report Wednesday?](https://longbridge.com/en/news/301623976.md)
- [Microsoft hits a big milestone that solidifies its revival](https://longbridge.com/en/news/301623691.md)
- [ASML Holding's Next Earnings Report on Oct. 14 Could Send the Stock Soaring. Here's Why.](https://longbridge.com/en/news/301605565.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**